Neural Precursor Cells Are Protected from Apoptosis Induced by Trophic Factor Withdrawal or Genotoxic Stress by Inhibitors of Glycogen Synthase Kinase 3

Received for publication, April 9, 2007, and in revised form, May 21, 2007 Published, JBC Papers in Press, June 4, 2007, DOI 10.1074/jbc.M702973200

Tae-Yeon Eom1, Kevin A. Roth1, and Richard S. Jope1,2

From the 1Department of Psychiatry and Behavioral Neurobiology and 2Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0017

Mechanisms controlling the survival of neural precursor cells (NPCs) are critical during brain development, in adults for neuron replenishment, and after transplantation for neuron replacement. This investigation found that glycogen synthase kinase 3 (GSK3) promotes apoptotic signaling in cultured NPCs derived from embryonic mouse brain subjected to two common apoptotic conditions, trophic factor withdrawal and genotoxic stress. Trophic factor withdrawal activated GSK3 and the key apoptosis mediators Bax and caspase-3. Pharmacological inhibition of GSK3 activity produced dramatic reductions in the activation of Bax and caspase-3 and NPC death after trophic factor withdrawal. Trophic factor withdrawal-induced apoptosis was delayed in Bax knock-out NPCs, but GSK3 inhibitors provided additional protection. Genotoxic stress induced by camptothecin treatment of NPCs stabilized p53, which formed a complex with GSK3β and activated Bax and caspase-3. Camptothecin-induced activation of caspase-3 was reduced by GSK3 inhibitors in both bax+/+ and bax−/− NPCs. Thus, NPCs are sensitive to loss of trophic factors and genotoxic stress, and inhibitors of GSK3 are capable of enhancing NPC survival.

Because many NPCs may be lost to apoptosis, GSK3 promotes apoptosis, and GSK3 inhibitors are available to block GSK3-facilitated apoptosis, GSK3 may be a favorable target for bolstering neurogenesis. To investigate this possibility with apoptotic conditions that NPCs may encounter either during development or with cytotoxic stresses, we exposed NPCs to trophic factor withdrawal or to the DNA damaging agent camptothecin. The results demonstrate that NPCs die by apoptosis involving Bax and caspase-3 activation after trophic factor withdrawal or DNA damage, and GSK3 inhibitors attenuate apoptotic signaling in NPCs exposed to each of these conditions.

MATERIALS AND METHODS

Cell Culture and Treatments—NPCs were prepared at gestational day 12–13 from the telencephalons of C57BL/6 mice (National Cancer Institute, Frederick, MD) or knock-out bax−/− mice and matched controls (28). Cells were dissociated for 18 min at 37 °C in Hanks’ balanced salt solution (Invitrogen) containing 0.05% trypsin, 0.02% EDTA, 0.001% DNase I, and 0.01% collagenase.
0.2% BSA (Sigma). After treatment with trypsin, an equal volume of Hanks’ balanced salt solution with 10% fetal bovine serum was added, and cells were further dissociated by trituration four times. Cells were washed and resuspended in Dulbecco’s modified Eagle’s medium containing 20 ng/ml fibroblast growth factor 2 (FGF2; Research Diagnostics, Flanders, NJ), 8 μg/ml heparin, 5 μg/ml insulin, 100 μg/ml apotransferrin, 30 μM sodium selenite, 20 nm progesterone, 100 μm putrescine, 6 g/liter glucose, 2 mM glutamine, 94.4 μM 2-mercaptoethanol, 100 units/ml penicillin, and 100 μg/ml streptomycin (Sigma), pH 7.4. NPCs were expanded as neurospheres, and experimental procedures were carried out with monolayers of NPCs. To prepare monolayers, the neurospheres were resuspended and incubated for 2 min at 37 °C in Hanks’ balanced salt solution with 0.05% trypsin, 0.02% EDTA, 0.2% BSA, diluted with 2 volumes of Dulbecco’s modified Eagle’s medium with 10% fetal calf serum, and plated on poly-L-lysine/laminin-coated culture plates and grown as monolayers for ~24 h. Tropic factor withdrawal was established by placing NPCs in Dulbecco’s modified Eagle’s medium/F-12 media without any additions. DNA damage was induced by treating cells with 10 μM camptothecin (Sigma) in NPC growth factor-containing media with FGF2. Where indicated, cells were treated with the selective GSK3 inhibitors 20 mM lithium, 5 μM kenpaullone (Sigma), 5 μM 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole (marketed as GSK3 Inhibitor II; Calbiochem), 20 μM indirubin-3’-monoxime (Alexis Biochemicals, San Diego, CA), or 5 μM SB216763 (Tocris Cookson Inc., Ballwin, MO).

**Immunoblot Analysis and Immunoprecipitation**—For immunoblotting, cells were washed twice with PBS and lysed with 100 μl of lysis buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 100 μM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 5 μg/ml pepstatin A, 1 mM okadaic acid, and 1% Triton-X-100). The lysates were centrifuged at 14,000 rpm for 20 min at 4 °C. Protein concentrations were determined using the Bradford method (29). Immunoprecipitations were performed using sheep anti-mouse IgG Dynabeads (Dynal Biotech, Oslo, Norway). The Dynabeads, 10 μl of slurry per sample, were washed twice in PBS, 0.1% BSA using a magnetic particle separator. The beads were incubated with 1 μg of anti-GSK3β antibody overnight at 4 °C with gentle agitation followed by incubation with protein samples for 1 h at 4 °C, and the immune complexes were washed 3 times. Samples were mixed with Laemmli sample buffer (2% SDS) and placed in a boiling water bath for 5 min. Proteins were resolved in SDS-polyacrylamide gels, transferred to nitrocellulose, and incubated with primary antibodies to poly(ADP-ribose) polymerase (PARP), proteolyzed PARP 85-kDa fragment (1:1000; dilution; Pharmingen/Transduction Laboratories), total GSK3α/β (1:2000), phospho-Ser-9-GSK3β (1:1000), phospho-Ser21-GSK3α (1:1000), GSK3β (1:2000), Akt (1:1000), phospho-Thr32-Akt (1:1000), phospho-Ser473-Akt (1:1000), Bak (1:1000), Bcl-XL (1:1000), BAX (1:1000), or cleaved, active caspase-3 (1:500; Cell Signaling, Beverly, MA). Immunoblots were developed using horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit IgG followed by detection with enhanced chemiluminescence, and the protein bands were quantitated with a densitometer. Quantitative measurements from at least three independent experiments were tested for statistical significance using analysis of variance.

**Immunocytochemistry**—NPCs cultured on poly-L-lysine/laminin-coated glass coverslips were treated as described under “Results.” Cells were fixed in 4% paraformaldehyde and then permeabilized and blocked in PBS, pH 7.4, containing 0.2% Triton X-100 and 3% BSA. Cells were incubated overnight at 4 °C with primary antibodies diluted in PBS containing 3% BSA, including mouse anti-nestin (1:40,000; Developmental Studies Hybridoma Bank, Iowa City, Iowa), mouse anti-glial fibrillary acidic protein (1:10,000; Chemicon), mouse anti-β-tubulin isotype III (1:10,000; Sigma), rabbit anti-activate caspase-3 (1:50; Cell Signaling), or mouse anti-active Bax (1:1000; Pharmingen/Transduction Laboratories), a conformational-specific Bax antibody that recognizes an epitope on Bax that is internalized in non-activated Bax but is externalized after apoptosis signaling-induced activation of Bax (30). The primary antibody was removed, the cells were washed three times with PBS and then incubated with either tyramide signal amplification...
PerkinElmer Life Sciences) with cyanine 3-tyramide-conjugated or with fluorescein isothiocyanate-conjugated secondary antibodies for 1 h at room temperature. Nuclei were labeled with 1 μg/ml bisbenzimide (Sigma) for 10 min at room temperature. NPCs were then washed three times with PBS, and coverslips were adhered to glass slides in mounting medium (0.1% p-phenylenediamine in 75% glycerol in PBS). Cells were viewed and photographed with an inverted Nikon fluorescence microscope. Positively stained cells were counted in at least 12 fields from a minimum of 3 different NPC preparations, and the total number of cells counted was always greater than 5000. Quantitative measurements from at least three independent experiments were tested for statistical significance using analysis of variance.

**Cell Viability**—Chromatin condensation was determined by fluorescence microscopy after nuclear staining with Hoechst dye. Dead cells were quantified by propidium iodide staining and fluorescence-activated cell sorter analysis. For this, after treatments NPCs were trypsinized, fixed in ethanol at −20 °C for 10 min, and rehydrated by adding PBS at room temperature for 15 min. Cells were stained with 3 μM propidium iodide in staining buffer (100 mM Tris, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% Nonidet P-40) for 15 min at room temperature and analyzed on a single-laser flow cytometer (BD Biosciences). Quantitative measurements from at least three independent experiments were tested for statistical significance using analysis of variance except for the data in supplemental Fig. 2b where Student’s t test was used to determine statistical significance.

**RESULTS**

Characterization of NPCs and Trophic Factor Withdrawal-induced Apoptosis—Isolated NPCs were expanded as neurospheres and then plated as monolayers (supple-
GSK3 Promotes Apoptosis in NPCs

Trophic factor withdrawal caused NPCs to undergo time-dependent activation of caspase-3 and cleavage of the caspase-3 substrate PARP beginning 3 h after trophic factor withdrawal (Fig. 1a). Immunocytochemistry verified the widespread activation of caspase-3 in NPCs 6 h after trophic factor withdrawal (Fig. 1b). Furthermore, morphological changes characteristic of apoptotic cells were also observed, such as chromatin condensation evident in Hoechst-stained NPCs 6 h after trophic factor withdrawal (Fig. 1c).

Trophic Factor Withdrawal Induces Dephosphorylation of Akt and GSK3—Growth factors often maintain cell viability in part by activating the phosphatidylinositol 3-kinase/Akt signaling pathway (26). When activated, Akt is phosphorylated on Ser-473 and Thr-308, and Akt catalyzes phosphorylation of GSK3 on a regulatory serine which inhibits its activity (26, 32). Therefore, we examined if this pathway was inactivated after trophic factor withdrawal by using phospho-dependent antibodies to detect phosphorylation of the regulatory sites on Akt and GSK3 in immunoblot analyses. Trophic factor withdrawal caused a rapid dephosphorylation of Akt on both Ser-473 and Thr-308, whereas the total level of Akt remained unchanged (Fig. 2a). Concomitant with the dephosphorylation of Akt, there was loss of serine phosphorylation of the two isoforms of GSK3, phospho-Ser-21-GSK3α and phospho-Ser-9-GSK3β, whereas the total protein levels of GSK3α/β were unchanged after trophic factor withdrawal (Fig. 2b). Quantitative analyses of these changes suggests that Akt is likely an important kinase for phosphorylating these serines in GSK3 in NPCs since there was concomitant dephosphorylation of Akt and GSK3 but also that other kinases contribute to serine phosphorylation of GSK3 since the dephosphorylation of serine-phosphorylated GSK3 was not as complete as was the dephosphorylation of Akt. These results demonstrate that trophic factor withdrawal led to a rapid inactivation of Akt and decrease of inhibitory serine phosphorylation of GSK3 before activation of caspase-3.

We tested if inclusion of a single growth factor was sufficient to block the trophic factor withdrawal-induced dephosphorylations of Akt and GSK3 and if this attenuated apoptotic signaling. For this, NPCs were incubated for 4 h in complete trophic factor withdrawal media or with the addition of 50 ng/ml FGF2 or 50 ng/ml insulin-like growth factor-1 (IGF-1). Stimulation with IGF-1, but not FGF2, was sufficient to maintain phosphorylation of Akt on both Ser-473 and Thr-308 (Fig. 2c) and inhibition-associated phosphorylation of GSK3α on Ser-21 and 95048a0
GSK3 Promotes Apoptosis in NPCs

![Image](22860-JBC-282-22860-g001)

FIGURE 4. GSK3 inhibitors reduce trophic factor withdrawal-induced Bax activation. a, immunocytochemical comparison of Bax activation (red) in control NPCs and after 4 h of trophic factor withdrawal. Nuclei were labeled with bisbenzimide (blue). Scale bar, 40 μm. b, treatment with 20 μM lithium (Li), 5 μM kenpaullone (Kp), or 5 μM SB216763 (SB) attenuated trophic factor withdrawal-induced Bax activation (means ± S.E.; n = 3; *p < 0.001). c, cellular protein levels of Bax, Bak, and Bcl-XL were not changed during trophic factor withdrawal.

GSK3β on Ser-9 (Fig. 2d). Stimulation with IGF-1 also abrogated the activation of caspase-3 and cleavage of PARP, whereas FGF2 was without effect (Fig. 2e).

Inhibition of GSK3 Protects NPCs from Trophic Factor Withdrawal-induced Caspase-3 Activation—Because GSK3 is known to be an important contributor of apoptotic signaling in many types of cells (20), we tested if inhibition of GSK3 protected NPCs from trophic factor withdrawal-induced caspase-3 activation. Treatment with the selective GSK3 inhibitor lithium (22) reduced trophic factor withdrawal-induced decreases of the inhibitory serine phosphorylation of both isoforms of GSK3 (Fig. 3a) and strongly inhibited trophic factor withdrawal-induced caspase-3 activation and PARP proteolysis between 4 and 8 h after withdrawal (Fig. 3b). To verify that this protective effect of lithium was due to inhibition of GSK3, four other selective inhibitors of GSK3 were tested along with lithium. These experiments demonstrated that NPCs were protected from trophic factor withdrawal-induced caspase-3 activation by 5 μM kenpaullone, 5 μM GSK3 inhibitor II, 20 μM indirubin-3′-monoxime, and 5 μM SB216763 (33–35), similar to the protection provided by 20 μM lithium (Fig. 3c). Quantitation showed that these five selective GSK3 inhibitors provided 80–95% protection from caspase-3 activation after 4 h of trophic factor withdrawal (Fig. 3d), verifying that inhibition of GSK3 provides NPCs protection from trophic factor withdrawal.

NPC viability was measured after 4, 8, and 12 h of trophic factor withdrawal by fluorescence-activated cell sorter analysis with propidium iodide staining to test if GSK3 inhibition maintained NPC viability (supplemental Fig. 2a). Lithium treatment reduced cell death by 50% after trophic factor withdrawal (supplemental Fig. 2b), and comparison of three GSK3 inhibitors showed that all provided at least 50% protection from cell death 12 h after trophic factor withdrawal (Fig. 3e). Taken together, these results demonstrate that in NPCs trophic factor withdrawal causes rapid dephosphorylation of Akt and GSK3 and caspase-3 activation, and GSK3 inhibitors substantially reduce caspase-3 activation and enhance the viability of NPCs, supporting the conclusion that GSK3 facilitates apoptotic signaling in NPCs.

The activation of Bax is a key step in the apoptotic signaling cascade (17, 36). When Bax is activated in the cytosol it translocates to the mitochondria where it promotes the disruption of mitochondria and the ensuing activation of caspases. Apoptosis-associated activated Bax can be detected with a conformational-specific Bax antibody (30). Immunocytochemistry demonstrated a large increase of activated Bax in NPCs after trophic factor withdrawal (Fig. 4a). Trophic factor withdrawal-induced Bax activation was significantly attenuated by treatment with three different GSK3 inhibitors, 20 μM lithium, 5 μM kenpaullone, or 5 μM SB216763 (Fig. 4b). Trophic factor withdrawal did not alter the cellular level of Bax or two other bcl-2 family members, Bak and Bcl-XL (Fig. 4c). These results demonstrate that GSK3 promotes the apoptotic signaling cascade at least in part by promoting apoptotic signaling upstream of Bax activation in NPCs subjected to trophic factor withdrawal.

Because trophic factor withdrawal-induced apoptosis activated Bax, GSK3 has been reported to contribute to Bax activation (37) and GSK3 inhibitors attenuated Bax activation, we tested if Bax was required for trophic factor withdrawal-induced caspase-3 activation or protection by GSK3 inhibitors. These questions were examined by using NPCs isolated from bax−/− mouse embryos. Caspase-3 activation and the associated proteolysis of PARP caused by trophic factor withdrawal were substantially delayed in Bax-null NPCs compared with matched wild-type control NPCs (Fig. 5a). However, caspase-3 activation was still attenuated by inhibition of GSK3 in Bax-null NPCs (Fig. 5, b and c). This indicates that although GSK3 promotes Bax activation, GSK3 also promotes apoptotic signaling by additional mechanisms independent of Bax that are upstream of caspase-3 activation in the trophic factor withdrawal-induced apoptotic signaling pathway.

DNA Damage-induced Apoptosis in NPCs—Apoptotic signaling in NPCs also was induced by the DNA-damaging agent camptothecin, a topoisomerase I inhibitor that induces apoptosis through a p53-dependent mechanism (38, 39). Camptothecin (10 μM) treatment of NPCs maintained in trophic factor-containing media caused a time-dependent increase in the level
p53 co-immunoprecipitated with GSK3

activation after camptothecin treatment (supplemental Fig.

were increased with an

treatment reduced caspase-3 activation

and PARP proteolysis in NPCs from Bax knock-out embryos. Camptothecin

treatment caused a large increase in active Bax immunoreactivity

in NPCs from wild-type mice (supplemental Fig. 3b). This is in accordance with previous reports that Bax is an important intermediate in genotoxic stress-induced apoptosis in NPCs (28, 31, 40). Bax activation in response to camptothecin administration was attenuated by treatment with four different GSK3 inhibitors (Fig. 7a). In Bax-null NPCs, the camptothecin-induced increase of caspase-3 activation was retarded compared with wild-type NPCs (Fig. 7b). To examine if caspase-3 activation induced by DNA damage in bax−/− NPCs is also promoted by GSK3, we tested the effects of several GSK3 inhibitors. Pretreatment with lithium inhibited DNA damage-induced activation of caspase-3 and PARP cleavage between 4 and 8 h after treatment of Bax-null NPCs with camptothecin (Fig. 7c). Protection by GSK3 inhibition was confirmed by treatment with two other selective GSK3 inhibitors, indirubin-3′-monoxime and SB216763, which attenuated caspase-3 activation (Fig. 7d). These results indicate that GSK3 promotes DNA damage-induced apoptosis in NPCs, promoting both Bax activation and a Bax-independent mechanism leading to caspase-3 activation.

**DISCUSSION**

This investigation sought to identify signaling mechanisms regulating the balance between the survival and death of NPCs. NPCs were found to be vulnerable to trophic factor withdrawal and to genotoxic stress, each causing activation of apoptotic signaling involving Bax and caspase-3. Inhibition of GSK3 greatly diminished activation of apoptotic signaling caused by each of these conditions. Thus, GSK3 activity makes an important contribution to shifting the balance from survival to apoptosis in NPCs, and this facilitation of apoptotic signaling by GSK3 is amenable to pharmacological modulation to diminish apoptosis in NPCs.

Deficintrophic factor supply rapidly activated the apoptotic signaling cascade in NPCs, similarly to apoptosis in mature neurons after trophic factor withdrawal (43). Trophic factors support cell viability by activating a variety of signaling pathways, one of which is the phosphatidylinositol 3-kinase/Akt pathway (26, 32). This signaling activity was quickly arrested after trophic factor withdrawal from NPCs, as indicated by the rapid dephosphorylation of Akt that signifies its inactivation. GSK3 is one of the important targets of Akt (20), and trophic factor withdrawal reduced the inhibitory serine phosphorylation of GSK3β in parallel with the inactivation of Akt. Conversely, stimulating NPCs with IGF-1 (which activates the phosphatidylinositol 3-kinase/Akt pathway) reactivated Akt and inhibited GSK3, and IGF-1 treatment was sufficient to block activation of caspase-3. After the dephosphorylation of Akt and of GSK3 induced by trophic factor withdrawal, Bax was

of p53 between 2 and 8 h after treatment, indicative of DNA damage (Fig. 6a). Active, cleaved caspase-3 and cleaved PARP were increased with an ~2 h delay after p53 accumulation (Fig. 6a). Immunocytochemistry confirmed the increased caspase-3 activation after camptothecin treatment (supplemental Fig. 3a). Furthermore, camptothecin-induced accumulated nuclear p53 co-immunoprecipitated with GSK3β (Fig. 6b). These results are in agreement with previous reports that after DNA damage NPCs undergo apoptosis by a mechanism dependent on p53 and caspase-3 (28, 31, 40) and that in other cell types GSK3β binds p53 in the nucleus after DNA damage to promote subsequent apoptotic signaling (42, 43).

Inhibition of GSK3 Protects NPCs from DNA Damage-induced Apoptosis—Inhibition of GSK3 with lithium modestly reduced the accumulation of p53, whereas it greatly attenuated camptothecin-induced activation of caspase-3 and cleavage of PARP (Fig. 6c). The effects of lithium were compared with three other inhibitors of GSK3, kenpaullone, GSK3 inhibitor II, and indirubin-3′-monoxime, 4 h after camptothecin treatment (Fig.

**FIGURE 5. GSK3 inhibitors protect from apoptosis even in the absence of Bax. a, comparison of the time courses of caspase-3 activation and PARP cleavage in NPCs from wild-type and Bax knock-out embryos during trophic factor withdrawal (TFW). b, lithium treatment reduced caspase-3 activation and PARP proteolysis in NPCs from Bax knock-out embryos. β-Actin was used as loading control. c, caspase-3 activation caused by trophic factor withdrawal (6 h) in NPCs from Bax knock-out embryos was reduced by treatment with the GSK3 inhibitors 20 mM lithium (Li), 5 μM kenpaullone (Kp), 20 μM indirubin-3′-monoxime (Ind), or 5 μM SB216763 (SB) (means ± S.E.; n = 3; * p < 0.001). Ctl, control.**
activated, and this was followed by activation of caspase-3, an executioner caspase. The finding that trophic factor withdrawal induced apoptosis in NPCs is in accordance with previous evidence that lack of trophic factor support impairs neurogenesis in vivo, although in vivo measurements of neurogenesis often entail the summation of proliferation and survival. For example, supplying exogenous growth factors increased neurogenesis in developing and adult rodent brain (44–50), and administration or overexpression of growth factors decreased NPC apoptosis in vivo (51–53).

In addition to finding that trophic factor withdrawal induced apoptotic signaling in NPCs, we identified GSK3 as an important modulator of this signaling, as a panel of GSK3 inhibitors effectively attenuated the activation of both Bax and caspase-3. Although each of these inhibitors is not entirely specific for GSK3, the only common target among them all is GSK3 (27). Furthermore, whereas lithium inhibits GSK3 by competing with magnesium, the others are structurally diverse inhibitors competitive with ATP. These inhibitors showed that the pro-apoptotic action of GSK3 was targeted partially upstream of Bax activation but was not entirely dependent on Bax since inhibition of GSK3 still provided protection from trophic factor withdrawal in Bax-null NPCs.

Genotoxic stress also activated apoptosis in NPCs, and this was attenuated by inhibitors of GSK3. A key protein activated by genotoxic stress is the tumor suppressor p53. Although normally a short-lived protein, DNA damage activates signaling pathways leading to the stabilization of p53, a transcription factor capable of inducing the expression of pro-apoptotic proteins (56). In accordance with these characteristics of p53 in other types of cells, DNA damage induced in NPCs by camptothecin caused a rapid increase in the level of p53 that preceded the activation of caspase-3. Stabilized p53 formed a complex with GSK3 in NPCs, and although inhibition of GSK3 had little effect on the accumulation of p53, it attenuated the progression of apoptotic signaling to caspase-3 activation, similar to reports in other cell types that GSK3 promotes p53-mediated apoptosis (41, 42, 57). Attenuation of the DNA damage-induced apoptotic signaling cascade by GSK3 inhibitors included suppression of the activation of Bax. That blocking Bax activation reduces apoptosis corroborates previous findings, also shown here, that Bax deficiency partially protects NPCs from genotoxic stress-induced apoptosis (28, 31, 40). However, additional actions of GSK3 were evident because caspase-3 activation was attenuated by GSK3 inhibitors in Bax-deficient NPCs.

The sites at which GSK3 acts to promote apoptosis still remain uncertain. Previous studies have indicated that GSK3 promotes apoptotic signaling both by enhancing signals that lead to the disruption of mitochondrial integrity and by regulating the expression of proteins that modulate apoptotic signaling (20). Bax activation is a key step in many apoptotic conditions, including apoptosis in cortical neurons after DNA damage (38, 58) and trophic factor deprivation (59) as well as in NPCs (60). Furthermore, GSK3 has been reported to activate Bax by direct phosphorylation (37). In NPCs, Bax was activated after both trophic factor withdrawal and camptothecin-in-
GSK3 Promotes Apoptosis in NPCs

The pro-survival effects of GSK3 inhibitors may underlie previous reports that neurogenesis is enhanced by lithium in vivo (61) and in cultured cells (62, 63). However, those studies did not identify the mechanism by which lithium enhanced neurogenesis, so other actions cannot be excluded, but the pro-apoptotic actions of GSK3 make it a prime target of lithium. Endogenous NPCs die by apoptosis, but the estimated death rates vary tremendously (12–14, 55). Apoptosis also underlies the elimination of most NPCs after transplantation (15). However, complete elimination of apoptosis of NPCs is detrimental, as indicated by studies of neurogenesis in transgenic mice in which apoptosis is greatly impaired, such as in caspase-3 (54) or Bax (59) knock-out mice. Caspase-3-deficient mice displayed embryonic or early postnatal lethality associated with a decrease in cell death, and Bax deficiency reduced naturally occurring developmental neuronal and progenitor cell death (28, 59). Therefore, agents that only shift the balance from death toward survival may provide a nonlethal intervention for improving the survival rate of NPCs without overburdening the brain with excessive cells. The current results showing that GSK3 promotes apoptotic signaling and that inhibitors of GSK3 provide protection raise the possibility that inhibitors of GSK3 may be useful agents to promote the survival of NPCs.

Acknowledgments—We thank Drs. R. S. Akhtar and B. Clodfelder-Miller for help establishing NPC cultures.

REFERENCES

1. Lie, D. C., Song, H., Colamarino, S. A., Ming, G. L., and Gage, F. H. (2004) Annu. Rev. Pharmacol. Toxicol. 44, 399–421
2. Abrous, D. N., Koehl, M., and Le Moal, M. (2005) Physiol. Rev. 85, 523–569
3. Haughey, N. J., Nath, A., Chan, S. L., Borchard, A. C., Rao, M. S., and Mattson, M. P. (2002) J. Neurochem. 83, 1509–1524
4. Imitola, J., Snyder, E. Y., and Khoury, S. J. (2003) Physiol. Genomics 14, 171–197
5. Lazic, S. E., Grote, H., Armstrong, R. J., Blakemore, C., Hannan, A. J., van Dellen, A., and Barker, R. A. (2004) Neuroreport 15, 811–813
6. Duman, R. S., Malberg, J., Nakagawa, S., and D’Sa, C. (2000) Biol. Psychiatry 48, 732–739
7. Jacobs, B. L., Prasad, H., and Gage, F. H. (2000) Mol. Psychiatry 5, 262–269
8. Malberg, I. E., Eisch, A. J., Nestler, E. J., and Duman, R. S. (2000) J. Neurosci. 20, 9104–9110
9. Manev, H., Uz, T., Smallheiser, N. R., and Manev, R. (2001) Eur. J. Pharmacol. 411, 67–70
10. Manev, H., Uz, T., Smallheiser, N. R., and Manev, R. (2001) Eur. J. Pharmacol. 411, 67–70
10. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., Belzung, C., and Hen, R. (2003) Science 301, 805–809
11. Jin, K., Lafave-bernt, M., Sun, Y., Chen, S., Gafni, J., Crippen, D., Logvinova, A., Ross, C. A., Greenberg, D. A., and Ellerby, L. M. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 18189–18194
12. Blaschke, A. J., Staley, K., and Chun, J. (1996) Development 122, 1165–1174
13. Thomaidou, D., Mione, M. C., Cavanagh, J. F., and Parnavelas, J. G. (1997) Development 124, 150–157
14. Blaschke, A. J., Staley, K., and Chun, J. (1996) J. Neurosci. Res. 43, 368–372
15. Bakshi, A., Keck, C. A., Koshkin, V. S., LeBold, D. G., Siman, R., Snyder, E. T., and McIntosh, T. K. (1999) Brain Res. 805–809
16. Lossi, L., and Merighi, A. (2003) Proc. Natl. Acad. Sci. U. S. A. 93, 8455–8459
17. Akhtar, R. S., Ness, J. M., and Roth, K. A. (2004) Biochim. Biophys. Acta 1644, 189–203
18. Pap, M., and Cooper, G. M. (1998) J. Biol. Chem. 273, 19929–19932
19. Bijur, G. N., De Sarno, P., and Jope, R. S. (2000) J. Biol. Chem. 275, 7583–7590
20. Beurel, E., and Jope, R. S. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 1165–1174
21. Beurel, E., and Jope, R. S. (2000) J. Biol. Chem. 275, 24887–24897
22. Jope, R. S. (1999) Annu. Rev. Neurosci. 22, 177–197
23. Stambolic, V., Ruel, L., and Woodgett, J. R. (1996) Trends Biochem. Sci. 21, 2056–2068
24. Jope, R. S. (1999) Mol. Cell. Neurosci. 14, 237–248
25. Jope, R. S. (2000) Trends Neurosci. 23, 453–501
26. Schneider, A., Kruger, C., Steigleder, T., Weber, D., Gassler, N., Laage, R., Aronowski, J., Maurer, M. H., Gassler, N., Mier, W., Hasselblatt, M., Kollmar, R., Schwab, S., Sommer, C., Bach, A., Kuhn, H. G., and Schabitz, W. R. (2005) J. Clin. Investig. 115, 2083–2098
27. Kuida, K., Zheng, T. S., Na, S., Kwan, C., Yang, D., Karasuyama, H., Rakic, P., and Flavell, R. A. (1996) Nature 384, 368–372
28. D’Sa-Eipper, C., Leonard, J. R., Putcha, G., Zheng, T., Flavell, R. A., Rakic, P., Kuida, K., and Roth, K. A. (2001) Development 128, 137–146
29. D’Sa, C., Klocke, B. J., Cecconi, F., Lindsten, T., Thompson, C. B., Korsmeyer, S. J., Flavell, R. A., and Roth, K. A. (2003) J. Neurosci. Res. 74, 435–445
30. Woodgett, J. R. (2001) Molec. Cell. Neurosci. 20, 11205–11213
31. D’Sa, C., Klocke, B. J., Cecconi, F., Lindsten, T., Thompson, C. B., Korsmeyer, S. J., Flavell, R. A., and Roth, K. A. (2003) J. Neurosci. Res. 74, 435–445
32. Woodgett, J. R. (2005) Curr. Opin. Cell Biol. 17, 150–157
33. Coghlan, M. P., Culbertt, A. A., Cross, D. A., Pancorbo, S. L., Yates, I. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee, C. L., Mills, D., Brown, M. J., Haigh, D., Ward, R. W., Smith, D. G., Murray, K. J., Reith, A. D., and Holder, J. C. (2000) Chem. Biol. 7, 793–803
34. Leclerc, S., Garnier, M., Hoesl, R., Marko, D., Snyder, G. L., Greengard, P., Biemb, J. A., Snyder, G. L., Greenberg, P. A., Lazdunski, M., and Meijer, L. (2000) Eur. J. Biochem. 267, 5983–5994
35. Leclerc, S., Garnier, M., Hoesl, R., Marko, D., Snyder, G. L., Greengard, P., Biemb, J. A., Snyder, G. L., Greenberg, P. A., Lazdunski, M., and Meijer, L. (2001) J. Biol. Chem. 276, 251–260
36. Cregan, S. P., MacLaurin, J. G., Craig, C. G., Robertson, G. S., Nicholson, D. W., Park, D. S., and Slack, R. S. (1999) J. Neurosci. 19, 7860–7869
37. Linseman, D. A., Butts, B. D., Precht, T. A., Phelps, R. A., Le, S. S., Laessig, T. A., Bouchard, R. I., Flores-Clay, M. L., and Heidenreich, K. A. (2004) J. Neurosci. 24, 9993–10002
38. Xiang, H., Kinoshita, Y., Knudson, C. M., Korsmeyer, S. J., Schwartzkroin, P. A., and Morrison, R. S. (1998) J. Neurosci. 18, 1363–1373
39. Morris, E. J., Keramas, E., Rideout, H. J., Slack, R. S., Dyson, N. J., Stefani, L., and Park, D. S. (2001) J. Neurosci. 21, 5017–5026
40. Akhtar, R. S., Geng, Y., Klocke, B. J., and Roth, K. A. (2006) Cell Death Differ. 13, 1727–1739
41. Watcharatisit, P., Bijur, G. N., Zmiraijewksa, I. W., Song, L., Zmiraijewska, A., Chen, X., Johnson, G. W. V., and Jope, R. S. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7951–7955
42. Watcharatisit, P., Bijur, G. N., Song, L., Zhu, J., Chen, X., and Jope, R. S. (2003) J. Biol. Chem. 278, 48872–48879
43. Oppenheim, R. W. (1991) Ann. Rev. Neurosci. 14, 435–451
44. Kuhn, H. G., Winkler, J., Kempermann, G., Thal, L. J., and Gage, F. H. (1997) J. Neurosci. 17, 5820–5829
45. Cameron, H. A., Hazel, T. G., and McKay, R. D. (1998) J. Neurobiol. 36, 287–306
46. Wagner, I. P., Black, I. B., and DiCicco-Bloom, E. (1999) J. Neurosci. 19, 6006–6016
47. Aberg, M. A., Aberg, N. D., Hedbacker, H., Oscarsson, J., and Eriksson, P. S. (2000) J. Neurosci. 20, 2896–2903
48. Lichtenwalner, R. J., Forbes, M. E., Bennett, S. A., Lynch, C. D., Sonntag, W. E., and Riddle, D. R. (2001) Neuroscience 107, 603–613
49. Jin, K., Mao, X. O., Sun, Y., Xie, L., Jin, L., Nishi, E., Klugsbrun, M., and Greenberg, D. A. (2002) J. Neurosci. 22, 5365–5373
50. Sun, Y., Jin, K., Childs, J. T., Xie, L., Mao, X. O., and Greenberg, D. A. (2006) Dev. Biol. 299, 329–335
51. Popken, G. J., Hodge, R. D., Ye, P., Zhang, J., Ng, W., O’Kusky, J. R., and D’Ercole, A. J. (2004) Eur. J. Neurosci. 25, 2056–2068
52. Schanzer, A., Wachs, F. P., Wilhelm, D., Acker, T., Cooper-Kuhn, C., Beck, H., Winkler, J., Aigner, L., Plate, K. H., and Kuhn, H. G. (2004) Brain Pathol. 14, 237–248
53. Popken, G. J., Hodge, R. D., Ye, P., Zhang, J., Ng, W., O’Kusky, J. R., and D’Ercole, A. J. (2004) Eur. J. Neurosci. 25, 2056–2068